Rewired Metabolism in Drug-resistant Leukemia Cells

Background: Drug resistance is a common problem in cancer chemotherapy. Results: Transcriptomic and metabolomic data show that resistant leukemia cells exhibit reduced glutamine dependence, enhanced glucose dependence, and altered fatty acid metabolism. Conclusion: The metabolism of resistant leukemia cells is fundamentally rewired. Significance: Understanding the metabolic cost of resistance can lead to novel therapeutic strategies. Cancer cells that escape induction therapy are a major cause of relapse. Understanding metabolic alterations associated with drug resistance opens up unexplored opportunities for the development of new therapeutic strategies. Here, we applied a broad spectrum of technologies including RNA sequencing, global untargeted metabolomics, and stable isotope labeling mass spectrometry to identify metabolic changes in P-glycoprotein overexpressing T-cell acute lymphoblastic leukemia (ALL) cells, which escaped a therapeutically relevant daunorubicin treatment. We show that compared with sensitive ALL cells, resistant leukemia cells possess a fundamentally rewired central metabolism characterized by reduced dependence on glutamine despite a lack of expression of glutamate-ammonia ligase (GLUL), a higher demand for glucose and an altered rate of fatty acid β-oxidation, accompanied by a decreased pantothenic acid uptake capacity. We experimentally validate our findings by selectively targeting components of this metabolic switch, using approved drugs and starvation approaches followed by cell viability analyses in both the ALL cells and in an acute myeloid leukemia (AML) sensitive/resistant cell line pair. We demonstrate how comparative metabolomics and RNA expression profiling of drug-sensitive and -resistant cells expose targetable metabolic changes and potential resistance markers. Our results show that drug resistance is associated with significant metabolic costs in cancer cells, which could be exploited using new therapeutic strategies.

[1]  M. Kanda,et al.  Prognostic impact of expression and methylation status of DENN/MADD domain-containing protein 2D in gastric cancer , 2015, Gastric Cancer.

[2]  Pawel Zajac,et al.  Base Preferences in Non-Templated Nucleotide Incorporation by MMLV-Derived Reverse Transcriptases , 2013, PloS one.

[3]  W. Isaacs,et al.  Tracking the clonal origin of lethal prostate cancer. , 2013, The Journal of clinical investigation.

[4]  Matthew G. Vander Heiden,et al.  Metabolic targets for cancer therapy , 2013, Nature Reviews Drug Discovery.

[5]  P. Borst,et al.  P-glycoprotein ABCB1: a major player in drug handling by mammals. , 2013, The Journal of clinical investigation.

[6]  I. T. de Almeida,et al.  Substrate specificity of human carnitine acetyltransferase: Implications for fatty acid and branched-chain amino acid metabolism. , 2013, Biochimica et biophysica acta.

[7]  M. Radermacher,et al.  MCJ/DnaJC15, an Endogenous Mitochondrial Repressor of the Respiratory Chain That Controls Metabolic Alterations , 2013, Molecular and Cellular Biology.

[8]  K. Borden,et al.  Mechanisms and insights into drug resistance in cancer , 2013, Front. Pharmacol..

[9]  M. Tan,et al.  Targeting cellular metabolism to improve cancer therapeutics , 2013, Cell Death and Disease.

[10]  Pier Paolo Pandolfi,et al.  Cancer metabolism: fatty acid oxidation in the limelight , 2013, Nature Reviews Cancer.

[11]  Yan Liu,et al.  Suppression of non-small cell lung cancer proliferation and tumorigenicity by DENND2D. , 2013, Lung cancer.

[12]  J. W. Clendening,et al.  Targeting tumor cell metabolism with statins , 2012, Oncogene.

[13]  Dania Daye,et al.  Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis. , 2012, Seminars in cell & developmental biology.

[14]  A. Lucci,et al.  Selection of Metastatic Breast Cancer Cells Based on Adaptability of Their Metabolic State , 2012, PloS one.

[15]  Pawel Zajac,et al.  Highly multiplexed and strand-specific single-cell RNA 5′ end sequencing , 2012, Nature Protocols.

[16]  B. Sikic,et al.  Molecular Pathways: Regulation and Therapeutic Implications of Multidrug Resistance , 2012, Clinical Cancer Research.

[17]  S. Bates,et al.  Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[18]  J. Ricci,et al.  Cancer metabolism: current perspectives and future directions , 2012, Cell Death and Disease.

[19]  T. Hankemeier,et al.  Identifying static and kinetic lipid phenotypes by high resolution UPLC-MS: unraveling diet-induced changes in lipid homeostasis by coupling metabolomics and fluxomics. , 2011, Journal of proteome research.

[20]  J. Chi,et al.  Glutamine Synthetase Is a Genetic Determinant of Cell Type–Specific Glutamine Independence in Breast Epithelia , 2011, PLoS genetics.

[21]  S. Linnarsson,et al.  Characterization of the single-cell transcriptional landscape by highly multiplex RNA-seq. , 2011, Genome research.

[22]  R. Deberardinis,et al.  Pyruvate carboxylase is required for glutamine-independent growth of tumor cells , 2011, Proceedings of the National Academy of Sciences.

[23]  F. Sigaux,et al.  Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse , 2011, The Journal of experimental medicine.

[24]  M. Karlsson,et al.  Inverse relationship between leukaemic cell burden and plasma concentrations of daunorubicin in patients with acute myeloid leukaemia. , 2011, British journal of clinical pharmacology.

[25]  T. Hankemeier,et al.  In vivo D2O labeling to quantify static and dynamic changes in cholesterol and cholesterol esters by high resolution LC/MS[S] , 2011, Journal of Lipid Research.

[26]  W. Huber,et al.  which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets , 2011 .

[27]  A. Grefhorst,et al.  Fenofibrate Simultaneously Induces Hepatic Fatty Acid Oxidation, Synthesis, and Elongation in Mice* , 2009, The Journal of Biological Chemistry.

[28]  Cole Trapnell,et al.  Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.

[29]  James R. Downing,et al.  Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia , 2008, Science.

[30]  R. Agarwal,et al.  Transient ectopic expression as a method to detect genes conferring drug resistance , 2008, International journal of cancer.

[31]  Katrin Hoffmann,et al.  Prediction of relapse in paediatric pre‐B acute lymphoblastic leukaemia using a three‐gene risk index , 2008, British journal of haematology.

[32]  Sui Huang,et al.  PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition , 2008, Proceedings of the National Academy of Sciences.

[33]  G. Siuzdak,et al.  Multiple ionization mass spectrometry strategy used to reveal the complexity of metabolomics. , 2008, Analytical chemistry.

[34]  C. Hoppel,et al.  Fatty acid chain‐elongation in perfused rat heart: Synthesis of stearoylcarnitine from perfused palmitate , 2007, FEBS letters.

[35]  T. Szczepański,et al.  Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia , 2007, Journal of Cancer Research and Clinical Oncology.

[36]  R. Barrantes,et al.  Methylation-Controlled J Protein Promotes c-Jun Degradation To Prevent ABCB1 Transporter Expression , 2007, Molecular and Cellular Biology.

[37]  Robert Brown,et al.  Epigenetic inactivation of MCJ (DNAJD1) in malignant paediatric brain tumours , 2006, International journal of cancer.

[38]  Robert Brown,et al.  Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene. , 2003, Carcinogenesis.

[39]  L. Hartmann,et al.  Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer. , 2001, Cancer research.

[40]  A. Andoh,et al.  Alterations in intestinal microflora, faecal bile acids and short chain fatty acids in dextran sulphate sodium-induced experimental acute colitis in rats , 2001, European journal of gastroenterology & hepatology.

[41]  G. Andersson,et al.  Characterization of an anthracycline-resistant human promyelocyte leukemia (HL-60) cell line with an elevated MDR-1 gene expression. , 1995, Biochemical pharmacology.

[42]  K. Tserng,et al.  Metabolic origin of urinary 3-hydroxy dicarboxylic acids. , 1991, Biochemistry.

[43]  I. Tein.  Disorders of fatty acid oxidation. , 2013, Handbook of clinical neurology.

[44]  C. Bloomfield,et al.  Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia , 2013, Cancer.

[45]  J. Salk.  Clonal evolution in cancer , 2010 .

[46]  C. Roe,et al.  Evidence for a short-chain carnitine-acylcarnitine translocase in mitochondria specifically related to the metabolism of branched-chain amino acids. , 2000, Molecular genetics and metabolism.